clinical trial · NCT06435312
An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
UCB Biopharma SRL·phase3·enrolling by invitation·n = 8
Generalized Myasthenia GravisZilucoplan
brief summary
The purpose of this study is to assess the long-term safety and tolerability of an additional 52 weeks of Zilucoplan treatment administered by subcutaneous injection once daily in pediatric study participants
started
Nov 19, 2024
primary completion
Oct 26, 2027
completion
Nov 19, 2027
last updated
Apr 24, 2026
official title
An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Zilucoplan in Pediatric Study Participants With Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol